A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Sponsor
Janssen-Cilag Ltd.
Study ID
NCT07449234
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.

Key Dates

First listed
Mar 4, 2026
Start date
Feb 9, 2026
Status verified
May 2026
Primary completion
Mar 15, 2027
Completion
Sep 1, 2027

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Guselkumab: Switch from Ustekinumab
    Participants with moderate-to-severe psoriasis who are candidates for systemic treatment (according to the Guselkumab label) and who are medically indicated to switch from Ustekinumab or its biosimilar to Guselkumab can be included in this study. Only data available per clinical practice will be collected within this study.

Primary Outcome Measure

Percentage of Participants Achieving a Psoriasis Area and Severity Index (PASI) Score Less Than or Equal to (<=) 3 after Switching to Guselkumab at Week 28 [ Time Frame: At Week 28 ]

Central Contacts

Find similar trials

Nationwide
Psoriasis trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies